Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. [electronic resource]
Producer: 20170606Description: 677-684 p. digitalISSN:- 1526-632X
- Adult
- Clinical Decision-Making -- methods
- Decision Support Techniques
- Disability Evaluation
- Disease Progression
- Female
- Fingolimod Hydrochloride -- adverse effects
- Glatiramer Acetate -- adverse effects
- Humans
- Immunologic Factors -- adverse effects
- Leukoencephalopathy, Progressive Multifocal -- epidemiology
- Male
- Markov Chains
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Natalizumab -- adverse effects
- Randomized Controlled Trials as Topic
- Risk
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.